[Ad hoc announcement pursuant to Art. 53 LR] Roche’s giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer
Globenewswire·2025-11-18 14:00
At interim analysis, giredestrant demonstrated a statistically significant and clinically meaningful benefit versus standard-of-care endocrine monotherapyThese unprecedented results support its potential as a new standard-of-care endocrine therapy in the early-stage settingData to be presented at an upcoming medical meeting and shared with health authorities around the world lidERA is the second positive phase III readout for giredestrant following evERA presented at ESMO 20251 Basel, 18 November 2025 - Roc ...